Eli Lilly and Company, Novo Nordisk A/S, Gilead Sciences, Vertex Pharmaceuticals, and D-Wave Quantum are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture and market medicinal drugs and therapies. Their market value is driven by factors such as clinical trial outcomes, regulatory approvals, patent expiration dates and healthcare policy changes. Because drug pipelines can yield both breakthroughs and setbacks, these equities often carry a blend of high-growth potential and elevated risk. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of LLY traded down $10.14 during trading hours on Friday, reaching $630.73. The company had a trading volume of 9,390,196 shares, compared to its average volume of 3,995,079. The firm has a 50 day simple moving average of $776.36 and a 200-day simple moving average of $799.60. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $597.76 billion, a price-to-earnings ratio of 51.37, a PEG ratio of 1.06 and a beta of 0.44. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $972.53.
Read Our Latest Research Report on LLY
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Shares of NVO traded up $2.25 during trading hours on Friday, reaching $51.01. The company had a trading volume of 18,283,796 shares, compared to its average volume of 11,299,982. The firm has a 50 day simple moving average of $67.55 and a 200-day simple moving average of $71.81. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $227.77 billion, a price-to-earnings ratio of 14.00, a PEG ratio of 1.37 and a beta of 0.63. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $139.74.
Read Our Latest Research Report on NVO
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
NASDAQ:GILD traded up $8.77 during mid-day trading on Friday, hitting $119.05. 6,720,134 shares of the company's stock traded hands, compared to its average volume of 8,381,174. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The firm's 50 day simple moving average is $110.75 and its 200 day simple moving average is $107.25. Gilead Sciences has a 1 year low of $72.43 and a 1 year high of $121.38. The company has a market cap of $148.09 billion, a PE ratio of 25.10, a price-to-earnings-growth ratio of 0.70 and a beta of 0.33.
Read Our Latest Research Report on GILD
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of NASDAQ VRTX traded down $8.25 during midday trading on Friday, reaching $367.38. 1,941,223 shares of the stock were exchanged, compared to its average volume of 1,627,296. The company has a market capitalization of $94.34 billion, a P/E ratio of 26.29 and a beta of 0.44. Vertex Pharmaceuticals has a 52-week low of $367.20 and a 52-week high of $519.88. The stock has a 50 day moving average price of $452.30 and a 200-day moving average price of $465.93.
Read Our Latest Research Report on VRTX
D-Wave Quantum (QBTS)
D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Ocean, a suite of open-source python tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community.
Shares of NYSE QBTS traded down $0.18 during midday trading on Friday, reaching $17.00. 30,325,306 shares of the stock were exchanged, compared to its average volume of 69,163,766. The company has a market capitalization of $4.97 billion, a P/E ratio of -28.33 and a beta of 1.41. D-Wave Quantum has a 52-week low of $0.78 and a 52-week high of $20.56. The company has a current ratio of 20.73, a quick ratio of 20.61 and a debt-to-equity ratio of 0.15. The stock has a 50 day moving average price of $16.70 and a 200-day moving average price of $11.03.
Read Our Latest Research Report on QBTS
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
